Search

everythinglearnresearchcommunity

for

Search:↓

Kintor is launching pyrilutamide as a cosmetic for hair loss. Users discuss its potential, comparing it to Cosmerna.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

The conversation discusses hair cloning trials expected to start in 2020-2021 and mentions concerns about potential delays due to the Coronavirus. Treatments like Minoxidil, finasteride, and RU58841 are referenced.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

The conversation discusses the emotional struggle of hair shedding while using finasteride and minoxidil, with users sharing encouragement and tips like using hair fibers, cutting hair shorter, and trusting the process for eventual regrowth. Many users emphasize that shedding is temporary and a sign that the treatment is working, suggesting patience and temporary solutions like hats and hair fibers.

A user is interested in creating a hair growth serum using oleic acid, palmitoleic acid, and anhydrous ethanol, and seeks advice on sourcing these ingredients. Another user plans to mix these with minoxidil, which already contains ethanol, and mentions using RU58841.

The user discovered they had been using fake minoxidil for almost two years, which stopped working, and switched to finasteride, which slowed hair loss. They recently started using real minoxidil and noticed a shedding phase, indicating it might be effective.

The conversation discusses using Toppik hair fibers with topical Minoxidil and the potential impact on application. The user considers switching to oral Minoxidil and plans to consult a doctor about Finasteride.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

Hair cloning is still experimental and not yet available. Successful cloning is estimated to be available around 2035.

Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.

The conversation discusses DIY cosmetic procedures like PRP, mesotherapy, and micro-needling, with some users experimenting with Minoxidil, finasteride, and RU58841 for hair loss. It highlights a community of mostly older women performing these treatments themselves.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

Skepticism about hair loss research motivations, suggesting financial interests hinder finding a cure. Mentions treatments like minoxidil, finasteride, and dutasteride, but notes they are not cures.

CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

Dr. Gabel doesn't use Verteporfin because it's not FDA approved. The user is getting FUT and wants to minimize scarring and maximize hair regrowth.

The conversation discusses using estradiol and its derivatives for hair loss without causing feminization. Users mention alternatives like alfatradiol, topical 17b-Estradiol, and DIM (Diindolylmethane).

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

There have been no new effective hair loss treatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.

The conversation is about seeking new research on hair loss treatments beyond the commonly known ones like Minoxidil and Finasteride. Additions to the list of treatments include topical caffeine, alfatradiol, fluridil, stemoxydine, and upcoming treatments like TDM-105795 and verteporfin.

Minoxidil, finasteride, and RU58841 promote hair growth by different mechanisms, with minoxidil and prostaglandin E1 being specifically mentioned. Corticosteroids can also cause hair growth.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The conversation discusses skepticism about a new hair loss treatment called project K, which claims to replicate a chemical from UCLA research but is suspected to be a scam. The original poster plans to continue using oral minoxidil, finasteride, and dutasteride, along with microneedling, for hair regrowth.